Prevalence of CYP2C19 Genetic Polymorphism among Normal People and Patients with Hepatic Diseases.

IF 0.3 Q4 TRANSPLANTATION
International Journal of Organ Transplantation Medicine Pub Date : 2018-01-01 Epub Date: 2018-02-01
Z Hashemizadeh, S A Malek-Hosseini, P Badiee
{"title":"Prevalence of CYP2C19 Genetic Polymorphism among Normal People and Patients with Hepatic Diseases.","authors":"Z Hashemizadeh,&nbsp;S A Malek-Hosseini,&nbsp;P Badiee","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with hepatic diseases are treated with numerous drugs metabolized by cytochrome P450.</p><p><strong>Objective: </strong>To evaluate the frequencies of CYP2C19 variant alleles (*2, *3, and *17), genotypes, and phenotypes, and the relationship between the frequency of these alleles and the underlying hepatic diseases among patients with advanced liver diseases who were candidates for liver transplantation.</p><p><strong>Methods: </strong>The Study was conducted on 120 patients suffering from various hepatic disorders, candidates for liver transplantation, and 52 healthy volunteers. DNA was extracted from blood samples and analyzed by TaqMan SNP genotyping assay. The CYP2C19 genotypes were classified into poor, extensive, intermediate, and ultra-rapid metabolizer phenotypes.</p><p><strong>Results: </strong>Viral hepatitis was the most common cause of liver disease among studied patients. The frequencies of CYP2C19 alleles *1, *17, and *2 were 66.7% (160/240), 20.8% (50/240) and 12.5% (30/240), respectively. Allele CYP2C19*3 was not found in the studied population. The most prevalent genotypes were CYP2C19 *1/*1 (47.5%) and *1/*17 (24.2%). The predicted CYP2C19 phenotypes were extensive metabolizer (47.5%), heterozygote extensive metabolizer (45.9%), ultra-rapid metabolizer (5%), and poor metabolizer (1.6%). There was no significant difference between the frequencies of CYP2C19 genotypes between healthy people and patients. The distribution of CYP2C19 genotype frequencies was not significantly associated with the underlying disease conditions (p=0.472).</p><p><strong>Conclusion: </strong>The distribution of CYP2C19 genotype frequencies in Iranian healthy people and patients with various hepatic diseases was not significantly different. This may allow the physicians to predict a tailoring dose regimens based on the individual's metabolic capacity, decrease the risk of harmful side effects of the drugs, and optimize the treatment.</p>","PeriodicalId":14242,"journal":{"name":"International Journal of Organ Transplantation Medicine","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839627/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Organ Transplantation Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/2/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patients with hepatic diseases are treated with numerous drugs metabolized by cytochrome P450.

Objective: To evaluate the frequencies of CYP2C19 variant alleles (*2, *3, and *17), genotypes, and phenotypes, and the relationship between the frequency of these alleles and the underlying hepatic diseases among patients with advanced liver diseases who were candidates for liver transplantation.

Methods: The Study was conducted on 120 patients suffering from various hepatic disorders, candidates for liver transplantation, and 52 healthy volunteers. DNA was extracted from blood samples and analyzed by TaqMan SNP genotyping assay. The CYP2C19 genotypes were classified into poor, extensive, intermediate, and ultra-rapid metabolizer phenotypes.

Results: Viral hepatitis was the most common cause of liver disease among studied patients. The frequencies of CYP2C19 alleles *1, *17, and *2 were 66.7% (160/240), 20.8% (50/240) and 12.5% (30/240), respectively. Allele CYP2C19*3 was not found in the studied population. The most prevalent genotypes were CYP2C19 *1/*1 (47.5%) and *1/*17 (24.2%). The predicted CYP2C19 phenotypes were extensive metabolizer (47.5%), heterozygote extensive metabolizer (45.9%), ultra-rapid metabolizer (5%), and poor metabolizer (1.6%). There was no significant difference between the frequencies of CYP2C19 genotypes between healthy people and patients. The distribution of CYP2C19 genotype frequencies was not significantly associated with the underlying disease conditions (p=0.472).

Conclusion: The distribution of CYP2C19 genotype frequencies in Iranian healthy people and patients with various hepatic diseases was not significantly different. This may allow the physicians to predict a tailoring dose regimens based on the individual's metabolic capacity, decrease the risk of harmful side effects of the drugs, and optimize the treatment.

正常人与肝病患者CYP2C19基因多态性的研究
背景:肝脏疾病患者需要多种由细胞色素P450代谢的药物治疗。目的:评价晚期肝病肝移植候选者中CYP2C19变异等位基因(*2、*3、*17)的频率、基因型和表型,以及这些等位基因的频率与潜在肝脏疾病的关系。方法:对120例各种肝脏疾病患者、肝移植候选者和52名健康志愿者进行研究。从血样中提取DNA,采用TaqMan SNP基因分型法进行分析。CYP2C19基因型分为贫代谢型、广泛代谢型、中间代谢型和超快速代谢型。结果:病毒性肝炎是研究患者中最常见的肝脏疾病原因。CYP2C19等位基因*1、*17和*2的频率分别为66.7%(160/240)、20.8%(50/240)和12.5%(30/240)。在研究人群中未发现CYP2C19*3等位基因。最常见的基因型为CYP2C19 *1/*1(47.5%)和*1/*17(24.2%)。预测CYP2C19表型为广泛代谢型(47.5%)、杂合子广泛代谢型(45.9%)、超快速代谢型(5%)和不良代谢型(1.6%)。CYP2C19基因型频率在健康人与患者之间无显著差异。CYP2C19基因型频率分布与基础疾病无显著相关性(p=0.472)。结论:CYP2C19基因型频率在伊朗健康人与各种肝病患者中的分布无显著差异。这可能使医生能够根据个体的代谢能力预测量身定制的剂量方案,降低药物有害副作用的风险,并优化治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: The International Journal of Organ Transplantation Medicine (IJOTM) is a quarterly peer-reviewed English-language journal that publishes high-quality basic sciences and clinical research on transplantation. The scope of the journal includes organ and tissue donation, procurement and preservation; surgical techniques, innovations, and novelties in all aspects of transplantation; genomics and immunobiology; immunosuppressive drugs and pharmacology relevant to transplantation; graft survival and prevention of graft dysfunction and failure; clinical trials and population analyses in the field of transplantation; transplant complications; cell and tissue transplantation; infection; post-transplant malignancies; sociological and ethical issues and xenotransplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信